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Background:  Insufficient platelet inhibition is a major determinant of stent thrombosis (ST) although the etiology is multi-factorial. Platelet 
inhibition levels were investigated in patients with previous angiographically confirmed stent thrombosis (ST), myocardial infarction (MI) and 
controls.
Methods:  Using The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) we identified patients with angiographically confirmed ST 
(n=48) or MI (n=30) while on dual antiplatelet therapy within 6 months of percutaneous coronary intervention (PCI) and matched control patients 
(n=50 and n=28, for ST and MI respectively) with none of these events in the same setting. On-clopidogrel platelet reactivity was measured with 
VerifyNow™ P2Y12 and vasodilator stimulated phosphoprotein phosphorylation (VASP-P) assay.
Results:  The mean P2Y12 reaction units (PRU) was higher (246.8 ± 75.9 vs. 200.0 ± 82.7, p=0.001) in ST patients compared to controls. The 
optimal cut-off for ST was ≥222 PRU (area under the curve 0.69, p<0.001) in a receiver operating characteristics (ROC) analysis, which was identical 
to the cut-off level defined as the proportion of controls below the 30th percentile of P2Y12 inhibition distribution in patients with ST. The cut-off 
level resulted in 70.2% sensitivity and 67.3% specificity. There was no significant difference in mean PRU but a higher device-reported % inhibition 
(45.1 ± 23.8 vs. 32.1 ± 23.2, p=0.04) in patients with MI compared to controls. Results with the VASP-P assay were not related to the occurrence of 
ST or MI.
Conclusion: Stent thrombosis was associated with high on-clopidogrel platelet reactivity measured with VerifyNow™. Spontaneous MI in stented 
patients on clopidogrel treatment was not. There is, however, a substantial overlap in the clopidogrel platelet reactivity response between patients 
with and without on-treatment ST.
